Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis

Author:

Valerio Maria Rosaria1,Spadaro Pietro2,Arcanà Concetta2,Borsellino Nicolò3,Cipolla Calogero4,Vigneri Paolo5,Piazza Dario6ORCID,Gebbia Vittorio678ORCID

Affiliation:

1. Medical Oncology Unit, Policlinico Paolo Giaccone, University of Palermo, Italy

2. Medical Oncology Unit, Casa di Cura Villa Salus, Messina, Italy

3. Medical Oncology Unit, Hospital Buccheri La Ferla, Palermo, Italy

4. Surgical Oncology Unit, Policlinico Paolo Giaccone, Palermo, Italy

5. Medical Oncology Unit, Policlinico, Catania, Italy

6. GSTU Foundation for the Study of Tumors, Palermo, Italy

7. Department Promise, University of Palermo, Palermo, Italy

8. Medical Oncology Unit, La Maddalena Clinic for Cancer, Palermo, Italy

Abstract

A retrospective analysis of 70 patients with triple-negative or hormone-resistant advanced breast carcinoma who had not previously received chemotherapy was carried out. Patients received oral vinorelbine 60 mg/m2 on day 1 and 8, plus capecitabine 1000 mg/m2 bid for 14 consecutive days every 3 weeks. Overall response rate was 53% with a 9% complete response rate. Stable disease was recorded in 27% of the cases. Median progression-free survival was 7.9 months and median overall survival was 29.2 months. Toxicity was generally mild and easily manageable. These data demonstrate that this combination is feasible, safe and active as first-line treatment of triple-negative fully hormone-resistant advanced breast carcinoma patients.

Publisher

Future Science Ltd

Subject

Biotechnology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3